CompBrief BY VELARION

Companies Acorda Therapeutics, Inc.

Acorda Therapeutics CEO salary & total pay, FY2022: $984K

Acorda Therapeutics (ACOR) CEO salary, fiscal 2022: Ron Cohen was paid a salary of $625,000 and $984,150 in total compensation. Free brief. Every figure links to the company’s own filing.

Acorda Therapeutics, Inc. no longer files a proxy statement; its last pay data is FY2022.

All products and prices

Ron Cohen's complete compensation dossier

A PDF and a CSV sent to your email: Ron Cohen's pay in every fiscal year Acorda Therapeutics, Inc. reported it, line by line, with Ron Cohen's equity grants and Acorda Therapeutics, Inc.'s disclosed peer group where the company discloses them. Every row is cited to its filing.

One-time report. No refunds.

See an example →
CEO total pay$984,150CEO Ron Cohen · source
Say-on-pay support53.86%Latest vote · source
CEO vs. named peers33rd pct.Of 23 peer CEOs
CEO pay ratio5:1To the median employee · source

CEO pay, last three years

  • $1,504,419FY2020
  • $1,646,404FY2021
  • $984,150FY2022

CEO total pay was $984,150 in fiscal 2022, down from $1,646,404 in fiscal 2021.

FY2022: salary $625,000 · bonus $0 · stock awards $0 · option awards $0

Executives and directors

Frequently asked questions

Who was the highest-paid executive at Acorda Therapeutics, Inc. in fiscal 2022?
As disclosed, Ron Cohen (President and Chief Executive Officer) was the highest-paid executive at Acorda Therapeutics, Inc. in fiscal 2022, with total compensation of $984,150.
How does Acorda Therapeutics, Inc.'s chief executive pay compare to its disclosed peer group?
As disclosed, Ron Cohen's total compensation ranked at the 33rd percentile of Acorda Therapeutics, Inc.'s disclosed peer group.
What is Acorda Therapeutics, Inc.'s CEO-to-median employee pay ratio?
As disclosed, Acorda Therapeutics, Inc.'s CEO-to-median employee pay ratio was 5:1.
How did shareholders vote on Acorda Therapeutics, Inc.'s executive compensation?
As disclosed, 53.86% of shareholders supported Acorda Therapeutics, Inc.'s executive compensation in the latest say-on-pay vote.
How much does Acorda Therapeutics, Inc. spend in total on board compensation for fiscal 2022?
As disclosed, Acorda Therapeutics, Inc. reported total board compensation of $425,686 for fiscal 2022.

Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.

Full detail

Every table from the filing. Open any section.

Summary compensation table
Named executive officerSalaryBonusStock awardsOption awardsNon-equity incentivePension / NQDCAll otherTotal
Ron Cohen$625,000$0$0$0$350,000$0$9,150$984,150
President and Chief Executive Officer
Kerry Clem415,000000168,07509,150592,225
Chief Commercial Officer
Lauren Sabella366,000000155,12409,150530,274
Former Chief Operating Officer
Michael Gesser450,000000009,150459,150
Chief Finance Officer and Treasurer

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Named executive officerFY2022 totalFY2021 totalFY2020 totalΔ FY2021→2022
Ron Cohen$984,150$1,646,404$1,504,419↓ −662,254
Kerry Clem592,225662,374603,783↓ −70,149
Lauren Sabella530,274810,676758,606↓ −280,402
Michael Gesser459,150304,884—↑ +154,266

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

Incentive-plan design — the Compensation Discussion & Analysis

Our compensation program reflects a pay-for-performance philosophy designed to provide competitive, market-based total compensation that attracts, retains, and motivates highly-qualified employees. It links short-term and long-term cash and equity incentives to corporate and individual performance and aligns the interests of employees with stockholders to build long-term value.

CEO STI target (% of salary)—
CEO LTI target (% of salary)—
Independent consultantArnosti Consulting
Clawback policytrue
Anti-hedgingtrue
Anti-pledgingtrue
Equity grants and outstanding awards

No plan-based awards are on file for this fiscal year.

Outstanding equity awards at fiscal year-end 2022

ExecutiveAwardExercisableShares unvestedExercise priceMarket value unvested
Kerry ClemOption1,72311181.06—
Kerry ClemOption1,4051,0963.16—
Kerry ClemOption3,543—182.76—
Kerry ClemOption3,543—236.28—
Kerry ClemOption3,188—214.44—
Kerry ClemOption2,159—213.18—
Kerry ClemOption1,250—164.85—
Kerry ClemOption1,967—146.1—
Kerry ClemOption9,168—14.46—
Lauren SabellaOption6,706—182.76—
Lauren SabellaOption5,668—236.28—
Lauren SabellaOption5,972—214.44—
Lauren SabellaOption4,558—213.18—
Lauren SabellaOption1,834—164.85—
Lauren SabellaOption6,771—99—
Lauren SabellaOption2,198—81.06—
Lauren SabellaOption13,334—14.46—
Michael GesserOption21,25063,7503.74—
Ron CohenOption6,67344781.06—
Ron CohenOption24,99375,0073.64—
Ron CohenOption21,250—182.76—
Ron CohenOption16,799—236.28—
Ron CohenOption15,668—214.44—
Ron CohenOption11,455—213.18—
Ron CohenOption4,984—164.85—
Ron CohenOption36,417—14.46—
Director compensation
DirectorCash feesStock awardsOption awardsNon-equity incentiveAll otherTotal
John P. KelleyIndependent · Board Chair · Compensation Committee (Chair)$124,854—$2,636——$127,490
John VarianIndependent · Audit Committee81,440—33,391——114,831
Lorin J. RandallIndependent · Audit Committee (Chair) · Nominations and Governance Committee · Not standing for re-election76,000—2,636——78,636
Peder K. Jensen, M.DIndependent · Audit73,392—2,636——76,028
Sandra Panem, Ph.DIndependent · Compensation · Nominations and Governance (Chair)70,000—2,636——72,636

Board fee structure and ownership guideline

Annual cash retainer$50,000
Annual equity retainer—
Per board meeting fee—
Committee chair fees (audit / comp / nom-gov)20,000 / 20,000 / 10,000
Stock ownership guideline—

Total cost of the board

ComponentFY2022
Cash retainers and fees$425,686
Equity awards (grant-date value)$0
All other compensation$0
Total cost of the board$425,686

Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.

Peer group, and who names Acorda Therapeutics as a peer

Companies that benchmark against ACOR

No companies currently name ACOR as a compensation peer in their most recent disclosure.

This is the complete answer, not a partial one — the list is never padded.

Disclosed peer group — fiscal year 2022

The peer group as the company's own proxy names it, the “2022 Peer Group” and “2023 Peer Group” — the reference set behind the percentile above.

BDSX Biodesix Inc.RDHL Redhill Biopharma Ltd. Lucira Health, Inc. Theratechnologies Inc.BIOC Biocept Inc.PRPH Prophase Labs, Inc. Medexus Pharmaceuticals Inc. Nuvo Pharmaceuticals Inc. Biocept Inc.DERM Journey Medical Corp.AYTU Aytu BioPharma, Inc. Medexus Pharmaceuticals Inc.ALIM Alimera Sciences, Inc.OPTN OptiNose, Inc.STIM Neuronetics, Inc.RMTI Rockwell Medical, Inc.BDSX Biodesix Inc. Nuvo Pharmaceuticals Inc.DERM Journey Medical Corp.PRPH Prophase Labs, Inc.RDHL Redhill Biopharma Ltd.LHDX Lucira Health, Inc. Theratechnologies Inc.

Chief executive pay against the peer group

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.

RankCompanyFYChief executiveSalaryStock awardsOption awardsNon-equity incentiveTotal
1Neuronetics, Inc.2025Keith Sullivan$728,000$3,208,750$0$412,776$4,365,064
2OptiNose, Inc.2023Ramy Mahmoud646,994637,075656,245454,7402,414,265
3Biodesix Inc.2025Scott Hutton643,404356,849524,437710,2802,238,470
4Rockwell Medical, Inc.2025Mark Strobeck566,500612,040249,732453,2001,895,472
5Acorda Therapeutics, Inc.2022Ron Cohen625,00000350,000984,150
6Alimera Sciences, Inc.2022Richard Eiswirth580,000124,000242,3290964,198
7Aytu BioPharma, Inc.2026Joshua Disbrow608,15442,7500177,000844,854
—Redhill Biopharma Ltd.——————not in coverage universe
—Biocept Inc.——————not in coverage universe
—Prophase Labs, Inc.——————not in coverage universe
—Journey Medical Corp.——————not in coverage universe
—Lucira Health, Inc.——————not in coverage universe

Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

Incentive design against the same peers

CompanyAnnual incentive payoutLong-term vehicle mixPSU measures include TSRCompensation consultant
Acorda Therapeutics, Inc.not disclosedOption 100not disclosedArnosti Consulting
Alimera Sciences, Inc.not disclosedOption 75 · Restricted Stock 25not disclosednot disclosed
Aytu BioPharma, Inc.50%not disclosednot disclosedAlvarez and Marsal Holdings, LLC
Biocept Inc.not disclosednot disclosednot disclosednot disclosed
Biodesix Inc.110%not disclosednot disclosednot disclosed
Journey Medical Corp.not disclosednot disclosednot disclosednot disclosed
Lucira Health, Inc.not disclosednot disclosednot disclosednot disclosed
Neuronetics, Inc.not disclosednot disclosednot disclosedAlpine Rewards, LLC
OptiNose, Inc.not disclosednot disclosednot disclosedPearl Meyer & Partners, LLC
Prophase Labs, Inc.not disclosednot disclosednot disclosednot disclosed
Redhill Biopharma Ltd.not disclosednot disclosednot disclosednot disclosed
Rockwell Medical, Inc.not disclosednot disclosednot disclosedCompensia

Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.

Say-on-pay history and pay ratio
Meeting yearMeeting dateForAgainstAbstainSupportOutcome
20232023-06-225,543,8694,749,89618,18353.86%Passed
20222022-06-103,405,9341,250,12453,60273.15%Passed
20212021-06-023,083,087256,24734,06092.33%Passed
20192019-06-1937,961,055637,5773,694,73098.35%Passed
20182018-06-2732,317,2006,432,18329,95283.4%Passed
20172017-05-3136,450,9501,042,38213,86797.22%Passed

Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.

Say-on-pay — history, company’s computation

Meeting yearMeeting dateApproval — company’s computation
20232023-06-2253.86%a
20222022-06-1073.15%b
20212021-06-0292.33%c

a. Approved under the standard stated in the filing — “If a quorum is present, the votes cast "for" must exceed the votes cast "against" to approve, on an advisory basis, the compensation of our Named Executive Officers. || Abstentions: Abstentions and broker non-votes are not counted as votes "for" or "against" this proposal.”.

b. Approved under the standard stated in the filing — “If a quorum is present, the votes cast "for" must exceed the votes cast "against" to approve, on an advisory basis, the compensation of our Named Executive Officers. || Abstentions: Abstentions and broker non-votes are not counted as votes "for" or "against" this proposal.”.

c. Approved under the standard stated in the filing — “Abstentions and broker 4 non-votes are not considered votes "FOR" any candidate or as a "WITHHELD" vote and therefore will not affect the outcome of this proposal.”.

Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.

CEO pay ratio

Ratio (CEO : median employee)5 : 1
CEO total compensation$984,150
Median employee compensation$218,380
Insider trades since the proxy

Every insider equity transaction reported on Form 4 after the 2022 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.

InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
Dividend-equivalent accruals2023-06-22—4,800——4 insiders, 4 accrual rows
Thomas M. BurnsDirector2023-06-22A2,40000Derivative, Class A CommonForm 4 ↗

Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.

View all 5 transactions
InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
Peder JensenDirector2023-06-22A1,200$0$0Derivative, Class A CommonForm 4 ↗
John P. KelleyDirector2023-06-22A1,20000Derivative, Class A CommonForm 4 ↗
Sandra Panem PhdDirector2023-06-22A1,20000Derivative, Class A CommonForm 4 ↗
John VarianDirector2023-06-22A1,20000Derivative, Class A CommonForm 4 ↗
Thomas M. BurnsDirector2023-06-22A2,40000Derivative, Class A CommonForm 4 ↗
Sources (27 citations)

Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.

  • Section 01, Ron Cohen. DEF 14A, filed 2023-04-27. Section “Summary Compensation Table” · page 41. As printed: 984,150. View filing ↗
  • Section 01, Kerry Clem. DEF 14A, filed 2023-04-27. Section “Summary Compensation Table” · page 41. As printed: 592,225. View filing ↗
  • Section 01, Lauren Sabella. DEF 14A, filed 2023-04-27. Section “Summary Compensation Table” · page 41. As printed: 530,274. View filing ↗
  • Section 01, Michael Gesser. DEF 14A, filed 2023-04-27. Section “Summary Compensation Table” · page 41. As printed: 459,150. View filing ↗
  • Section 07, pay ratio. DEF 14A, filed 2023-04-27. Section “CEO Pay Ratio”. As printed: 5 : 1. View filing ↗
  • Section 08, John P. Kelley. DEF 14A, filed 2023-04-27. Section “Director Compensation”. As printed: 127,490. View filing ↗
  • Section 08, John Varian. DEF 14A, filed 2023-04-27. Section “Director Compensation”. As printed: 114,831. View filing ↗
  • Section 08, Lorin J. Randall. DEF 14A, filed 2023-04-27. Section “Director Compensation”. As printed: 78,636. View filing ↗
  • Section 08, Peder K. Jensen, M.D. DEF 14A, filed 2023-04-27. Section “Director Compensation”. As printed: 76,028. View filing ↗
  • Section 08, Sandra Panem, Ph.D. DEF 14A, filed 2023-04-27. Section “Director Compensation”. As printed: 72,636. View filing ↗
  • Section 02, Peder Jensen 2023-06-22. Form 4, filed 2023-06-23. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, John P. Kelley 2023-06-22. Form 4, filed 2023-06-23. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Sandra Panem Phd 2023-06-22. Form 4, filed 2023-06-23. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, John Varian 2023-06-22. Form 4, filed 2023-06-23. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Thomas M. Burns 2023-06-22. Form 4, filed 2023-06-23. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 06, 2023 vote. Form 8-K, filed 2023-06-27. Item 5.07 · say-on-pay result. As reported: 53.86% (votes for as printed: 5,543,869). View filing ↗
  • Section 06, 2022 vote. Form 8-K, filed 2022-06-13. Item 5.07 · say-on-pay result. As reported: 73.15% (votes for as printed: 3,405,934). View filing ↗
  • Section 06, 2021 vote. Form 8-K, filed 2021-06-04. Item 5.07 · say-on-pay result. As reported: 92.33% (votes for as printed: 3,083,087). View filing ↗
  • Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
  • Section 09b board cost (computed). Computed. Cash 425,686 + equity 0 + all other 0 = 425,686, summed across the director compensation table rows.
  • Neuronetics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-09. CEO total compensation as printed in Neuronetics, Inc.'s own proxy. As printed: 4,365,064. View filing ↗
  • OptiNose, Inc., Section 10b CEO total. DEF 14A, filed 2024-04-26. CEO total compensation as printed in OptiNose, Inc.'s own proxy. As printed: 2,414,265. View filing ↗
  • Biodesix Inc., Section 10b CEO total. DEF 14A, filed 2026-04-09. CEO total compensation as printed in Biodesix Inc.'s own proxy. As printed: 2,238,470. View filing ↗
  • Rockwell Medical, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in Rockwell Medical, Inc.'s own proxy. As printed: 1,895,472. View filing ↗
  • Acorda Therapeutics, Inc. (subject), Section 10b CEO total. DEF 14A, filed 2023-04-27. CEO total compensation as printed in Acorda Therapeutics, Inc.'s own proxy. As printed: 984,150. View filing ↗
  • Alimera Sciences, Inc., Section 10b CEO total. DEF 14A, filed 2023-06-29. CEO total compensation as printed in Alimera Sciences, Inc.'s own proxy. As printed: 964,198. View filing ↗
  • Aytu BioPharma, Inc., Section 10b CEO total. DEF 14A, filed 2026-10-22. CEO total compensation as printed in Aytu BioPharma, Inc.'s own proxy. As printed: 844,854. View filing ↗